Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS
Open Access
- 18 July 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 894872
Abstract
Guillain–Barré syndrome (GBS) is an autoimmune neurological disorder often preceded by viral illnesses or, more rarely, vaccinations. We report on a unique combination of postcoronavirus disease 2019 (COVID-19) vaccine GBS that occurred months after a parainfectious COVID-19–related GBS. Shortly after manifesting COVID-19 symptoms, a 57-year-old man developed diplopia, right-side facial weakness, and gait instability that, together with electrophysiology and cerebrospinal fluid examinations, led to a diagnosis of post-COVID-19 GBS. The involvement of cranial nerves and IgM seropositivity for ganglioside GD1b were noteworthy. COVID-19 pneumonia, flaccid tetraparesis, and autonomic dysfunction prompted his admission to ICU. He recovered after therapy with intravenous immunoglobulins (IVIg). Six months later, GBS recurred shortly after the first dose of the Pfizer/BioNTech vaccine. Again, the GBS diagnosis was confirmed by cerebrospinal fluid and electrophysiology studies. IgM seropositivity extended to multiple gangliosides, namely for GM3/4, GD1a/b, and GT1b IgM. An IVIg course prompted complete recovery. This case adds to other previously reported observations suggesting a possible causal link between SARS-CoV-2 and GBS. Molecular mimicry and anti-idiotype antibodies might be the underlying mechanisms. Future COVID-19 vaccinations/revaccinations in patients with previous para-/post-COVID-19 GBS deserve a reappraisal, especially if they are seropositive for ganglioside antibodies.Keywords
This publication has 19 references indexed in Scilit:
- Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A ReviewNeurology and Therapy, 2021
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2Cell, 2021
- The SARS-CoV-2 as an instrumental trigger of autoimmunityAutoimmunity Reviews, 2021
- Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19Biochemical and Biophysical Research Communications, 2021
- IgM autoantibodies recognizing ACE2 are associated with severe COVID-19medRxiv, 2020
- Guillain–Barré Syndrome Associated with SARS-CoV-2New England Journal of Medicine, 2020
- Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypesJournal of Neurology, Neurosurgery & Psychiatry, 2016
- Acute and chronic ataxic neuropathies with disialosyl antibodies: A continuous clinical spectrum and a common pathophysiological mechanismMuscle & Nerve, 2014
- Recurrent Guillain-Barre Syndrome Following VaccinationClinical Infectious Diseases, 2012
- Guillain-Barré syndromeThe Lancet, 2005